anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disorder characterized by an increased proliferation of immature T lymphocytes precursors. T-ALL treatment includes chemotherapy with strong side effects, and patients that undergo relapse display poor prognosis. Although cell-intrinsic oncogenic pathways are well-studied, the tumor microenvironment, like inflammatory cellular and molecular components is less explored in T-ALL. We sought to determine the composition of the inflammatory microenvironment induced by T-ALL, and its role in T-ALL progression. We show in two mouse T-ALL cell models that T-ALLs enhance blood neutrophils and resident monocytes, accompanied with a plasmatic acute secretion of inflammatory molecules. Depleting neutrophils using anti-Ly6G treatment or resident monocytes by clodronate liposomes treatment does not modulate plasmatic inflammatory molecule secretion and mice survival. However, inhibiting the secretion of inflammatory molecules by microenvironment with NECA, an agonist of adenosine receptors, diminishes T-ALL progression enhancing mouse survival. We uncovered Hepatocyte Growth Factor (HGF), T-ALL-driven and the most decreased molecule with NECA, as a potential therapeutic target in T-ALL. Altogether, we identified a signature of inflammatory molecules that can potentially be involved in T-ALL evolution and uncovered HGF/cMET pathway as important to target for limiting T-ALL progression.
Diabetic retinopathy (DR), a complex complication of diabetes mellitus (DM), is a leading cause of adult blindness. Hyperglycemia triggers DR, resulting in microvascular damage, glial apoptosis, and neuronal degeneration. Inflammation and oxidative stress play crucial roles during this process. Current clinical treatments for DR primarily target the advanced retinal disorder but offer limited benefits with inevitable side effects. Extracellular vesicles (EVs) exhibit unique morphological features, contents, and biological properties and can be found in cell culture supernatants, various body fluids, and tissues. In DR, EVs with specific cargo composition would induce the reaction of receptor cell once internalized, mediating cellular communication and disease progression. Increasing evidence indicates that monitoring changes in EV quantity and content in DR can aid in disease diagnosis and prognosis. Furthermore, extensive research is investigating the potential of these nanoparticles as effective therapeutic agents in preclinical models of DR. This review explores the current understanding of the pathological effects of EVs in DR development, discusses their potential as biomarkers and therapeutic strategies, and paves the way for further research and therapeutic advancements.
BACKGROUND AND PURPOSE: Chronic inflammation plays a pivotal role in the development of Type 2 diabetes mellitus (T2DM). Previous studies have shown that haem oxygenase-1 (HO-1) plays a proinflammatory role during metabolic stress, suggesting that HO-1 inhibition could be an effective strategy to treat T2DM. However, the application of HO-1 inhibitors is restricted due to solubility-limited bioavailability. In this study, we encapsulated the HO-1 inhibitor, zinc protoporphyrin IX (ZnPP), within nanoparticles and investigated their role in regulating glucose homeostasis and chronic inflammation during obesity.
EXPERIMENTAL APPROACH: We delivered DMSO-dissolved ZnPP (DMSO-ZnPP) and ZnPP-laden nanoparticles (Nano-ZnPP) to diet-induced obese male mice for 6 weeks. Glucose and insulin tolerance tests were carried out, liver and adipose tissue gene expression profiles analysed, and systemic inflammation analysed using flow cytometry.
KEY RESULTS: Nanoparticles significantly increased the delivery efficiency of ZnPP in both cells and mice. In mice with diet-induced obesity, inhibition of HO-1 by Nano-ZnPP significantly decreased adiposity, increased insulin sensitivity, and improved glucose tolerance. Moreover, Nano-ZnPP treatment attenuated both local and systemic inflammatory levels during obesity. Mechanistically, Nano-ZnPP significantly attenuated glucagon, TNF, and fatty acid synthesis signalling pathways in the liver. In white adipose tissue, the oxidative phosphorylation signalling pathway was enhanced and the inflammation signalling pathway diminished by Nano-ZnPP. Our results show that Nano-ZnPP has better effects on the improvement of glucose homeostasis and attenuation of chronic inflammation, than those of DMSO-dissolved ZnPP.
CONCLUSIONS AND IMPLICATIONS: These findings indicate that ZnPP-laden nanoparticles are potential therapeutic agents for treating T2DM.
Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
PURPOSE:To mold the nylon capsule capable of changing reversibly the membrane permeability in accordance with the subtle change of pH by filling >=1 kind of compd. shown by a specified general formula into the finely porous part of the nylon capsule. CONSTITUTION:A nylon capsule coated with a nylon film is formed by filling a bimolecular film compd. expressed by formulas I, II, III, and IV into the fine pores of nylon which is used as a base [in the formulas, (n) and (m) are 9-19 integer, and R is -(CH2)l-COOH wherein (l) is 1-5 integer]. The nylon capsule is manufactured by allowing diamine to react with a dibasic acid or by polymerizing or condensation-polymerizing lactam. The nylon capsule is dialyzed in a buffer soln. of a substance to be contained in the capsule, and the substance is contained in the hollow part of the capsule.
Participants who participated in either Study 1 or 2 are recruited. They will experience both electrical and heat stimuli.
This study aims to investigate the potential efficacy of a combination of two FDA-approved agents, sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM), for the purpose of smoking cessation treatment. DXM, a widely used over-the-counter cough suppressant, is a nicotine receptor antagonist. In fact, studies by Duke's Center for Smoking Cessation (CSC) have shown that administration of DXM leads to a decrease in self-administration of nicotine in nicotine-dependent rats. DXM, however, has not been studied in humans. DXM, when taken alone, is not expected to be useful for treating nicotine dependence in humans given DXM rapidly metabolizes in humans via CYP2D6. As a result, therapeutic concentrations needed to bind to nicotine receptors are not obtained. Therapeutic concentrations of DXM are required, therefore, to allow DXM to bind to nicotine receptors and act as a nicotine antagonist. In order to attain therapeutic concentrations of DXM a metabolism inhibitor must be introduced. BUP is a well-known FDA approved smoking cessation medication that has been shown to inhibit the metabolism of DXM. When BUP is co-administered with DXM to healthy volunteers, a significant increase in DXM plasma levels is observed.

Currently, Axsome Therapeutics Inc. (Axsome) is developing and testing an oral fixed-dose combination of IR DXM with SR BUP to achieve therapeutic concentrations of DXM. This investigational drug has been named AXS-05. Axsome has found AXS-05 to be generally safe and well-tolerated in three Phase 1 studies. The adverse event profile of AXS-05 was similar to that of BUP alone.

Given the distinct mechanisms by which BUP and DXM interact, it is hoped that combining DXM and BUP will prove more efficacious than either drug administered alone for the purpose of tobacco use treatment in humans.
Known risk loci for endometrial cancer explain approximately one third of familial endometrial cancer. However, the association of germline copy number variants (CNVs) with endometrial cancer risk remains relatively unknown. We conducted a genome-wide analysis of rare CNVs overlapping gene regions in 4115 endometrial cancer cases and 17,818 controls to identify functionally relevant variants associated with disease. We identified a 1.22-fold greater number of CNVs in DNA samples from cases compared to DNA samples from controls (p = 4.4 × 10-63). Under three models of putative CNV impact (deletion, duplication, and loss of function), genome-wide association studies identified 141 candidate gene loci associated (p < 0.01) with endometrial cancer risk. Pathway analysis of the candidate loci revealed an enrichment of genes involved in the 16p11.2 proximal deletion syndrome, driven by a large recurrent deletion (chr16:29,595,483-30,159,693) identified in 0.15% of endometrial cancer cases and 0.02% of control participants. Together, these data provide evidence that rare copy number variants have a role in endometrial cancer susceptibility and that the proximal 16p11.2 BP4-BP5 region contains 25 candidate risk gene(s) that warrant further analysis to better understand their role in human disease.
A transdermal delivery apparatus for delivering specific desired quantities of cream-base medicament or any flowable composition is disclosed. The apparatus comprises a revolving platform, a threaded screw-complex, a house, an applicator pad, and a safety cap. The revolving platform produces audible and tactile sensations upon interaction with projections from the house. The threaded screw-complex interacts with an elevator to transport the medicament upwards. The house confines an inner chamber to store the medicament. The applicator pad comprises a center outlet where the composition exits the chamber.
The invention relates to an ADAM17 inhibitor for use in the prevention and/or treatment of COVID-19 in a subject. The invention further relates to a pharmaceutical composition comprising an ADAM17 inhibitor as an active ingredient for use in the prevention and/or treatment of COVID-19 in a subject. The invention further relates to a kit of parts for use in the prevention and/or treatment of COVID-19 in a subject comprising i) an ADAM17 inhibitor and ii) a vaccine. The invention further relates to a pharmaceutical composition comprising an ADAM17 inhibitor and an active immunization vaccine. The invention further relates to a kit of parts comprising i) an ADAM17 inhibitor and ii) an active immunization vaccine. The invention further relates to a method of preventing and/or treating COVID- 19 in a subject, in the need thereof.
The pregnancy-specific syndrome preeclampsia is a leading cause of maternal and fetal morbidity and mortality. The underlying cause of preeclampsia is unknown, however several pre-existing maternal conditions are associated with an increased risk of preeclampsia including: diabetes, hypertension, renal dysfunction, obesity and history of preeclampsia. Specifically, the risk of preeclampsia is five times greater in women with diabetes.

Several lines of evidence indicate that endothelial dysfunction is a central feature of the pathophysiology of preeclampsia. Asymmetric dimethylarginine (ADMA) is a methylated metabolite of the amino acid L-arginine and an endogenous inhibitor of nitric oxide synthase (NOS). High concentrations of ADMA contribute to endothelial dysfunction and ADMA inhibits angiogenesis and arteriogenesis, activities important in pregnancy and deficient in preeclampsia. ADMA concentrations are higher early in pregnancy among women who later develop preeclampsia. This protocol describes a randomized placebo-controlled trial of L-citrulline in 40 pregnant women with type 2 diabetes from approximately sixteen to nineteen weeks gestation, to determine whether L-citrulline supplementation increases the plasma L-arginine/ADMA ratio, lowers maternal blood pressure and increases a circulating marker of placental function (placental growth factor PLGF).
The specification describes an economical process for the preparation of immunoglobulin for intravenous administration. An immunoglobulin can be, in accordance with the process, purified by a combination of a fractional precipitation method and an affinity chromatography. As a precipitant, divalent or trivalent metal salts are used and a complex of human IgG and a polyhydroxy polymeric compound is employed as an adsorbent. Purified immunoglobulin contains little or no aggregated or partially denatured globulin which is believed to cause anaphylaxis when administered intravenously. Prior art techniques cannot economically provide immunoglobulin in such a purified form and only intramuscular injections were feasible. Intravenous administrations allow immunoglobulin to be dosed in a larger amount and to act much faster than intramuscular injections.
Hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, product should be discontinued and physician consulted. Close patient supervision is recommended. 

Warnings: Avoid contact with eyes, nose, mouth, and lips.In case of accidental contact, patient should rinse thoroughly with water and contact a physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Provided are: a production method for a formulation composition from which it is possible to easily obtain a formulation that has a high hardness and excellent granulation properties while inhibiting degradation of a drug during production; and a production method for the formulation.　A production method for a formulation composition according to the present invention comprises step 1 for kneading and granulating, in a barrel, a mixture containing a filler, an active component, and a binding agent by twin-screw extrusion. The temperature in the barrel is at most 140°C. The mass-average molecular weight of the binding agent is at most 1,000,000 g/mol. The proportion of the filler and the active component contained in the mixture is 80-95 mass% with respect to the total mass of the filler, the active component, and the binding agent. The proportion of the filler contained in the mixture is 1-94 mass% with respect to the total mass of the filler, the active component, and the binding agent.
The invention relates to the technical field of molecular biology and immunology, in particular to a vascular endothelial cadherin epitope, an antibody and application thereof. The invention provides a vascular endothelial cadherin epitope, an antibody and application thereof. The epitope amino acid sequence is shown as SEQ ID NO. 1, is positioned at the N end of CDH5 protein and has higher conservation. The epitope provided by the invention is a neutralizing epitope, and can specifically recognize tumor blood vessels and inhibit the generation of the tumor blood vessels. Experiments prove that the epitope can specifically identify vascular endothelial cadherin in tumor vessels, so that the epitope plays a role in inhibiting tumor angiogenesis.
PROBLEM TO BE SOLVED: To obtain a composition for coating teeth, instantly curing in the oral cavity, providing a coating film of small thickness having antimicrobial activity itself. SOLUTION: This coating composition is obtained by dissolving 10-100 pts.wt. of a shellac in 100 pts.wt. of >=50% ethyl alcohol solution to give a solution of shellac in alcohol and dissolving one or two of 0.001-30 pts.wt. of a basic amino acid and 0.001-30 pts.wt. of a pH adjuster in the solution and can provide a surface having lost tack immediately after curing and showing a lubricant sensation.
The invention is based on receiving patient-specific acquisition values for acquiring an image data set. The acquisition parameters are determined by applying the trained mapping rules to patient-specific acquisition values. The training mapping is based on a plurality of training data sets, wherein the training data sets respectively comprise at least one patient-specific training image value and at least one training image parameter and at least one training image quality assessment. The inventors have recognized that the complex influence of patient-specific acquisition values and acquisition parameters on the imaging result is thereby quantified. The flexible and individual adaptation of the recording parameters is achieved by the training-quality evaluation being made by individual operators or specific groups of operators. In particular, the recording parameters can be determined such that the result of the imaging is individually adapted to the operator.
PURPOSE: To use an antagonist against platelet activating factor(PAF)-acether such as hydrophilic triazolothieno-diazepine for curing diseases such as coronary vessel-contraction, rapid edema formation in the skin, etc., caused by depression of vascular endothelial cell-barriers. CONSTITUTION: To cure diseases caused by depression of vascular endothelial cell-barriers, an antagonist against PAF-acether, e.g. a hydrophilic triazolothieno- diazepine (e.g. WEB2086), its homologue, a gingkolide (e.g.; BN52020), a synthetic gingkolide derivative or a homologue of the PAF-acether such as CV3988, is used. To determine the efficacy of the above antagonist, a primary mixture is prepared by taking a predetermined amount of vascular endothelial cells after culturing and washing and adding a marked PAF-acether, and a secondary mixture by adding an antagonist to be measured, the vascular endothelial cells are separated from the both mixtures and amounts of the bound marked PAF- acether in each of the mixtures are measured.
Usual practice during weeks 0-10. Intervention during weeks 11-20 (10 weekly group sessions).
There has been virtually no experience with overdosage with ranitidine injection and limited experience with oral doses of ranitidine. Reported acute ingestions of up to 18 g orally have been associated with transient adverse effects similar to those encountered in normal clinical experience (see ADVERSE REACTIONS). In addition, abnormalities of gait and hypotension have been reported.

When overdosage occurs, clinical monitoring and supportive therapy should be employed.

Studies in dogs receiving dosages of ranitidine hydrochloride in excess of 225 mg/kg/day have shown muscular tremors, vomiting, and rapid respiration. Single oral doses of 1,000 mg/kg in mice and rats were not lethal. Intravenous LD50 values in mice and rats were 77 and 83 mg/kg, respectively.
Gynecologic surgery with minimally invasive method using robotic or laparoscopic techniques has gained popularity for reducing perioperative discomfort and length of hospital stay. However, the debate over postoperative pain superiority between traditional laparoscopy and robotic surgery persist. This study compared the postoperative pain of patients within 24 h of robotic (RM) and laparoscopic myomectomy (LM). This retrospective cohort study included 24 and 53 patients who underwent RM and LM, respectively, between January 2019 and July 2023. The primary outcomes were the postoperative pain levels of patients within 24 h and the use and dosage of postoperative analgesia. Additional perioperative analgesia, including long-acting non-steroidal anti-inflammatory drugs (Dynastat) and abdominal nerve block, was also recorded. The secondary outcomes were blood loss and hospitalization duration. The patient characteristics were similar between the groups. Factors that could potentially increase pain, such as the number of ports (p < 0.0001), additional procedures (p = 0.0195), operative time (p < 0.0001), number of myomas (p = 0.0057), and the largest myoma size (p = 0.0086), were significantly higher in the RM group than in the LM group. However, there were no significantly different in the postoperative visual analog scale pain scores, use and dosage of ketorolac and opioid, and use of Dynastat and nerve block between the groups. Hospitalization duration and intraoperative blood loss were similar between the groups. RM and LM offer comparable postoperative pain outcomes, emphasizing the importance of patient-specific factors in decision-making regarding myomectomy techniques.
Newborns (treatment-group E) and infants at the age of 6 months (treatment-group L) shall be treated with 1 x 1 ml ECN-SUSPENSION for 10 days and observed until the age of 12 months.Treatment-group E (newborn) will receive EcN-Suspension on the first 10 days of life and will be observed for the next 12 months. Treatment-group L (infants at the age of 6 months) will receive EcN-Suspension on the first 10 days of their seventh month of life and will be observed for the next 6 months.The corresponding control group will remain untreated and will be observed only for 12 months. According to the hospitals daily routine the inclusion and exclusion criteria will be checked. All newborns meeting the inclusion criteria will be included into the trial. Patients' anamnestic data and general health status are recorded at the initial control.Controls are performed according to the time schedule normally used in the hospital functioning as a trial site. According to this, during each monthly control data on the efficacy and safety are recorded. The final control for assessing the tolerance and efficacy of the trial medication is conducted along with a physical examination after an observation period of 12 months.In this study, diarrhea is defined as increase of stool frequency to \>3 watery or loose stools in 24 hours on at least two or more consecutive days.The prophylaxis against gastrointestinal infections with EcN-Suspension is expected to result in a decrease of the number episodes of diarrhea in comparison to the untreated control. The primary efficacy criterion is the number of episodes of diarrhea caused by gastrointestinal infection within the first 12 months.
Compounds according to BE 704037 suitable for use as blood pressure depressants or for curing angina pectoris, Raynaud's disease, etc. have the formula: (inwhich R' is an arylalkyl wit 1-6C atoms in the alkyl gp. and the aryl gp. optionally substituted with one or more alkoxy or OH groups, or an aryloxyalkyl group with 1-6C atoms in the alkyl group and the aryloxy group opt. substituted with one or more alkoxy or OH gps.). Pharmaceutically acceptable acid addition salts of these compounds may also be used.